[{"address1": "41 Ninth Avenue", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10001", "country": "United States", "phone": "646 661 7661", "fax": "646 661 4027", "website": "https://www.ovidrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 40, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir", "age": 70, "title": "President, CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 1030026, "exercisedValue": 0, "unexercisedValue": 671250}, {"maxAge": 1, "name": "Mr. Jeffrey A. Rona", "age": 55, "title": "Chief Business and Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 761235, "exercisedValue": 0, "unexercisedValue": 104909}, {"maxAge": 1, "name": "Mr. Thomas Michael Perone J.D., M.B.A.", "age": 58, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 745711, "exercisedValue": 0, "unexercisedValue": 256927}, {"maxAge": 1, "name": "Mr. Jason  Tardio M.B.A.", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 652840, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Simon D. Kelner", "age": 49, "title": "Chief Human Resources Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dirk  Haasner", "age": 58, "title": "Senior Vice President of Global Manufacturing & CMC QA", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 416952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Todd F. Baumgartner M.D., M.P.H.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia  Tsai Ph.D.", "age": 48, "title": "Senior Vice President of Clinical Development", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Meg  Alexander", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Manoj  Malhotra M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.29, "open": 1.09, "dayLow": 1.08, "dayHigh": 1.12, "regularMarketPreviousClose": 3.29, "regularMarketOpen": 1.09, "regularMarketDayLow": 1.08, "regularMarketDayHigh": 1.12, "beta": 0.58, "forwardPE": -3.8928573, "volume": 4138125, "regularMarketVolume": 4138125, "averageVolume": 183680, "averageVolume10days": 125970, "averageDailyVolume10Day": 125970, "bid": 1.02, "ask": 1.15, "bidSize": 200, "askSize": 200, "marketCap": 77329616, "fiftyTwoWeekLow": 1.08, "fiftyTwoWeekHigh": 4.139, "priceToSalesTrailing12Months": 163.2477, "fiftyDayAverage": 3.1263, "twoHundredDayAverage": 3.3447, "currency": "USD", "enterpriseValue": 158846816, "floatShares": 40751303, "sharesOutstanding": 70944600, "sharesShort": 2850541, "sharesShortPriorMonth": 2798057, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0402, "heldPercentInsiders": 0.15874, "heldPercentInstitutions": 0.62442, "shortRatio": 20.65, "shortPercentOfFloat": 0.048800003, "impliedSharesOutstanding": 70944600, "bookValue": 1.106, "priceToBook": 0.98553354, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -50676960, "trailingEps": -0.72, "forwardEps": -0.28, "enterpriseToRevenue": 335.336, "enterpriseToEbitda": -2.594, "52WeekChange": -0.14434332, "SandP52WeekChange": 0.23763025, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "OVID", "underlyingSymbol": "OVID", "shortName": "Ovid Therapeutics Inc.", "longName": "Ovid Therapeutics Inc.", "firstTradeDateEpochUtc": 1493991000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "51982f47-ea34-3602-8b3b-2a8cb7696156", "messageBoardId": "finmb_288870432", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.09, "targetHighPrice": 11.0, "targetLowPrice": 3.5, "targetMeanPrice": 7.69, "targetMedianPrice": 8.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 90259000, "totalCashPerShare": 1.272, "ebitda": -61246180, "totalDebt": 15698000, "quickRatio": 10.138, "currentRatio": 10.465, "totalRevenue": 473695, "debtToEquity": 20.054, "revenuePerShare": 0.007, "returnOnAssets": -0.28094998, "returnOnEquity": -0.50874, "freeCashflow": -29240618, "operatingCashflow": -50354924, "revenueGrowth": 1.242, "grossMargins": 1.0, "operatingMargins": -117.682434, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-17"}]